RxDoctor Payments Data

Raymond Nwadiuko, MD

Allergy · Lanham, MDNPI 1255387288

Payments from drug & device makers

What this record shows

19 manufacturers reported payments, led by Pfizer at 48.4% of the total. Reporting peaked in 2020 at $2,673 and has fallen 73.6% since, to $705 in 2025. That places this record below the midpoint for allergy clinicians in MD, where the typical reported total is $7,148.

$5,353in general payments, 2019–2025

Across 117 payments — averaging $45.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$3K
  • Sanofi$808
  • GSK$691
  • AstraZeneca$460
  • Biocryst US Sales Co., LLC$235
  • Amgen$196
  • plus $373 from 13 others
$13,696in research payments, 2019–2025

Across 3 payments — averaging $4565.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$14K
  • Merck$62

What the payments were for

  • Speaking & faculty fees$2,59048%
  • Food & beverage$2,76352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,353 in reported general payments places this provider in the 40th percentile of 29 allergy providers in Maryland.

See all allergy providers in Maryland

Medicare billing

Part B allowed, 2024
$116,525
Medicare patients
77
Services billed
10,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SymbicortBudesonide/Formoterol Fumarate18$4,624
Wixela InhubFluticasone Propion/Salmeterol11$2,991
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,568
Montelukast Sodium55$740
Albuterol Sulfate HfaAlbuterol Sulfate19$629
Fluticasone Propionate34$544
Triamcinolone Acetonide13$279
Prednisone36$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$460$4,62418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 29 allergy providers in Maryland.

Other allergy in Lanham

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →